Meaningful and Sustained Weight Loss and Improvement of Lipid Profile in Hypogonadal Men on Long-Term Treatment with Testosterone Undecanoate (TU) Injections are Independent of Age: Observational Data from Two Registry Studies

Saad F1,2, Haider A1, Yassin A1,3, Doros G4, Traish A4
1Global Medical Affairs Andrology, Bayer Pharma, Berlin, Germany
2Gulf Medical University, Ajman, UAE
3Private Urology Practice, Bremerhaven, Germany
4Institute for Urology and Andrology, Norderstedt, Germany
*Dresden International University, Dresden, Germany
5Departments of Biochemistry and Urology, Boston University School of Public Health, Boston, Mass, USA
6Departments of Biochemistry and Urology, Boston University School of Medicine, Boston, Mass, USA

Introduction
Improvements of anthropometric and metabolic parameters on long-term testosterone replacement therapy (TRT) from our registry studies have been reported in 2013 (Saad, Obes; Yassin and Doros, Clin Obes; Traish, Int J Clin Prac).

Methods
561 hypogonadal men from both registry studies were divided into age groups ≤65 (Group A, n=450) and >65 years (Group B, n=111). All men were treated with three-monthly TU injections for up to 6 years.

Results
Mean weight (kg) decreased from 102.52 ± 15.56 to 90.15 ± 9.69 in Group A and from 102.83 ± 15.64 to 95.35 ± 9.03 in Group B. Model-adjusted mean change from baseline was -14.78 ± 0.35 and -15.14 ± 0.71 kg, resp. Percent change from baseline was -13.56 ± 7.56% in Group A and -13.28 ± 7.14% in Group B. Waist circumference (cm) decreased from 106.54 ± 9.03 to 98.26 ± 7.1 in Group A and from 108.95 ± 10.75 to 100.72 ± 9.45 in Group B. The mean change from baseline was 9.34 ± 0.2 cm in Group A and 10.45 ± 0.47 cm in Group B.

Body mass index (BMI; kg/m²) decreased from 32.58 ± 5.08 to 29.02 ± 3.01 in Group A and from 32.84 ± 4.86 to 30.35 ± 2.61 in Group B. The mean change from baseline was -4.72 ± 0.11 and -4.81 ± 0.22 kg/m², respectively (p <0.0001 for all).

Total cholesterol (mg/dl) decreased from 268.92 ± 45.95 to 193.56 ± 16.58 in Group A and from 268.44 ± 52.69 to 191.69 ± 21.8 in Group B, LDL (mg/dl) from 159.87 ± 36.7 to 119.81 ± 34.87 in Group A and from 162.48 ± 31.63 to 120.86 ± 33.56 in Group B, triglycerides (mg/dl) from 262.35 ± 73.16 to 192.1 ± 34.4 in Group A and from 266.9 ± 84.37 to 192.27 ± 32.16 in Group B. HDL (mg/dl) increased from 48.91 ± 17.33 to 59.55 ± 17.66 in Group A and from 51.64 ± 16.56 to 61.99 ± 18.67 in Group B. TC:HDL ratio improved from 6.35 ± 2.42 to 3.54 ± 1.04 in Group A and from 5.67 ± 2.09 to 3.32 ± 0.91 in Group B (p <0.0001 for all).

Conclusions
TRT in hypogonadal men resulted in meaningful and sustained weight loss and improvement of lipid profile independent of age.